Cited by 134Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal

Open access
Pitt, Jason, Roth, William, Lacor, Pascale, Smith, Amos B., Blankenship, Matthew, Velasco, Pauline, De Felice, Fernanda, Breslin, Paul +1 more·2009·Toxicology and Applied Pharmacology

Abstract

It now appears likely that soluble oligomers of amyloid-beta1-42 peptide, rather than insoluble fibrils, act as the primary neurotoxin in Alzheimer's disease (AD). Consequently, compounds capable of altering the assembly state of these oligomers (referred to as ADDLs) may have potential for AD therapeutics. Phenolic compounds are of particular interest for their ability to disrupt Abeta oligomerization and reduce pathogenicity. This study has focused on oleocanthal (OC), a naturally-occurring phenolic compound found in extra-virgin olive oil. OC increased the immunoreactivity of soluble Abeta species, when assayed with both sequence- and conformation-specific Abeta antibodies, indicating changes in oligomer structure. Analysis of oligomers in the presence of OC showed an upward shift in MW and a ladder-like distribution of SDS-stable ADDL subspecies. In comparison with control ADDLs, oligomers formed in the presence of OC (Abeta-OC) showed equivalent colocalization at synapses but exhibited greater immunofluorescence as a result of increased antibody recognition. The enhanced signal at synapses was not due to increased synaptic binding, as direct detection of fluorescently-labeled ADDLs showed an overall reduction in ADDL signal in the presence of OC. Decreased binding to synapses was accompanied by significantly less synaptic deterioration assayed by drebrin loss. Additionally, treatment with OC improved antibody clearance of ADDLs. These results indicate oleocanthal is capable of altering the oligomerization state of ADDLs while protecting neurons from the synaptopathological effects of ADDLs and suggest OC as a lead compound for development in AD therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.taap.2009.07.018

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Not all Aβ oligomers are toxic, even those of a given size; subtle conformation changes affect toxicity and immunoreactivity.

    “And in fact, not all oligomers are toxic, even those oligomers of a given size. Subtle conformation changes affect toxicity and immunoreactivity (Chromy et al., 2003; Pitt et al., 2009).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L.
Affiliations
  • Northwestern University (US)
  • Monell Chemical Senses Center (US)
  • Western Illinois University (US)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
  • Pitt, Jason
  • Breslin, Paul
  • Klein, William L.
Venue
Toxicology and Applied Pharmacology
Publisher
Elsevier BV
Published
2009-10
Volume
240
Issue
2
Pages
189-197
ISSN
0041-008X (ISSN-L)
OpenAlex
W2025825556
Cited by
134
References
53
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 11 · 2018: 12 · 2017: 13 · 2016: 9 · 2015: 10 · 2014: 5 · 2013: 15 · 2012: 17
FWCI
6.41
Type
journal article
Language
en
Open access
Locations
  • Toxicology and Applied Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
  • National Institutes of Health (5p50dc006760-05, 5t32ag020418-08)
  • National Institute on Aging (5 T32 AG020418, R01AG022547, R01AG029460, T32-AG020418)
  • National Institute on Deafness and Other Communication Disorders (P50 DC06760, P50-DC006760)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, amyloid-beta oligomers, oleocanthal, extra virgin olive oil, phenolic compounds, synaptotoxicity, oligomerization, immunoreactivity, drebrin, antibody clearance, neuroprotection, Alzheimer's disease therapeutics
MeSH terms
Cyclopentane Monoterpenes, Aldehydes, Animals, Antibodies, Antigen-Antibody Reactions, Cells, Cultured, Dose-Response Relationship, Drug, Electrophoresis, Polyacrylamide Gel, Fluorescent Antibody Technique, Hippocampus, Humans, Molecular Weight, Neuropeptides, Peptide Fragments, Phenols, Protein Conformation, Synapses, Immunoblotting, Amyloid beta-Peptides, Microscopy, Confocal, Neuroprotective Agents, Protein Multimerization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review